Abstract
Abstract
Objective
To explore the effect of Ludangshen oral liquid for treatment of convalescent patients with coronavirus disease 2019 (COVID-19) with randomized, double-blind, placebo-controlled multicenter method.
Methods
200 convalescent COVID-19 patients who had symptoms related to decreased digestive and respiratory function were randomly divided to either receive Ludangshen oral liquid or placebo for 2 weeks. The severity of clinical symptoms including fatigue, anorexia, abdominal distension, loose stools, and shortness of breath were assessed by visual analogue scale and observed at before and after treatment. The improvement and resolution rates of clinical symptoms were evaluated. Full analysis set (FAS) and per-protocol set (PPS) were used for statistical analyses. Adverse events were recorded during the study.
Results
8 patients did not complete the study. After 2 weeks of treatment, both FAS and PPS results showed that patients in Ludangshen group had significantly lower score of fatigue, anorexia, loose stools, and shortness of breath than placebo group (P < 0.05), while there was no significant difference in distention (P > 0.05). The improvement rate of fatigue, anorexia, distension, loose stools and shortness of breath were significantly higher in Ludangshen group (P < 0.05), as well as the resolution rates (P < 0.05) except for shortness of breath (P > 0.05). There were two cases of adverse events, with one nose bleeding in Ludangshen group and one headache in placebo group.
Conclusion
The study suggested that two weeks of Ludangshen oral liquid treatment may have certain effects for convalescent COVID-19 patients on improving digestive and respiratory symptoms including fatigue, anorexia, loose stools and shortness of breath, which may be one of the choices for management of convalescent COVID-19 patients with digestive and respiratory symptoms.
Funder
National Key R&D Program
State Administration of Traditional Chinese Medicine Special Project of Chinese Medicine Emergency Response to New Coronavirus Pneumonia
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine,Pharmacology
Reference23 articles.
1. Weekly Operational Update on COVID-19. https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---6-november-2020.
2. Commission NH. Translation: diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Infect Microbes Diseases. 2020;2(2):48–54.
3. Notice on issuing rehabilitation guidance for traditional Chinese medicine during the recovery period of New Coronavirus Pneumonia (Trial). http://www.gov.cn/zhengce/zhengceku/2020-02/24/content_5482544.htm.
4. Zai F, Mu L, Li P, Chang L, Wang X, Li Y, Zhang Q, Guo L, Li H. Intepretation of the rehabilitation guidance for traditional Chinese medicine during the recovery period of New Coronavirus Pneumonia (Trial). J Changzhi Med College (Chang Zhi Yi Xue Yuan Xue Bao). 2020;34(2):111–3.
5. Transcript of the Press Conference on February 17, 2020. http://www.nhc.gov.cn/xcs/fkdt/202002/f12a62d10c2a48c6895cedf2faea6e1f.shtml.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献